Placeholder Banner

Biotechnology is a national security Imperative, says BIO CEO

Crowley Sets Out BIO’s Strategic Direction on National security

March 13, 2024
Media Contact

BIO President & CEO John F. Crowley announced today that BIO would take several important steps to reaffirm the organization’s position with regards to national security and the role that the industry plays as a vital strategic asset:

“As a combat veteran and former Naval Intelligence Officer with JSOC and member of the U.S. Intelligence Community, I have a uniquely vivid perspective on the threats posed to the national security of America and our allies.  Specifically, the United States and our allies need a robust and vibrant American biotechnology industry.  Biotechnology is a vital strategic asset that is essential to strengthen and protect our public health generally, and as well in response to future pandemics and the potential for bioterrorism. It is also an essential element of our ability to project abroad the principles and benefits of a free and democratic society.

“The capabilities and capacity to create, manufacture and distribute state-of-the-art newer and better medicines and vaccines is the foundation for America to continue its essential role as the “World’s Medicine Chest.”  Our adversaries abroad have stated that they intend to become the biotechnology center of excellence in the world.  America and our allies cannot let this happen. Securing and advancing our preeminence in biomanufacturing will be one key component of a multi-prong approach to secure and advance this strategic imperative in biotechnology.”

As such, BIO is taking the following immediate steps:

  1. BIO will support the BIOSECURE Act and will work with Congress as this legislation progresses. BIO has members across the U.S. working on groundbreaking new medicines and biotechnologies. This breadth of experience and expertise provide BIO with unique perspectives into the types of policies and investments needed to ensure that the U.S. can continue to lead the world in this strategically important sector.
  2. BIO will work with policymakers on both sides of the aisle to ensure that we have the biomanufacturing and distribution capacity and capabilities so that no patient ever goes without the medicines they need. Biomanufacturing resiliency is a strategic imperative that is essential for long-term U.S. leadership and security.
  3. WuXi AppTec proactively ended its membership in BIO.

BIO also sent a letter to Rep. Michael Gallagher, chairman of the House Select Committee on the CCP, today stating its position and highlighting the importance of the biotechnology industry to national security. The letter reiterates BIO’s desire to work with Congress and the White House to develop policies and legislation that align with and advance a vibrant biotechnology industry for the United States and its allies.

*This statement has been updated on 3-14-2024 to reflect WuXi Apptec proactively ending it's relationship in BIO.

# # #

Discover More
 USTR this week released its 2022 Special 301 Report. BIO, after reviewing the report, released the following statement: We welcome USTR’s efforts to address IP-related concerns for U.S.-based biotech enterprises in China, especially…
The following statement can be attributed to BIO’s President and CEO Dr. Michelle McMurry-Heath in response to the ongoing conflict in Ukraine and the organization’s efforts to help in humanitarian relief: “The conflict in Ukraine and violence…
"The White House’s decision to send Covid-19 vaccines to countries in need is an important step to ensuring people around the globe have access to lifesaving shots and ending this global pandemic. “As part of BIO’s recently-proposed Global “SHARE”…